Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

2,774 public trials 698 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Completed

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00831597

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Pharmatech Oncology Study Site Beverly Hills, California, United States
  • Pharmatech Oncology Study Site Fountain Valley, California, United States
  • Pharmatech Oncology Study Site Oxnard, California, United States
  • Pharmatech Oncology Study Site Washington D.C., District of Columbia, United States
View all 33 locations
View Trial Details
Completed

Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma

NCT01369784

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Hospital de Elda Elda, Alicante, Spain
  • H. U. Germans Trias i Pujol Badalona, Barcelona, Spain
  • Hospital Clinic i Provincial Barcelona, Spain
  • Hospital del Mar Barcelona, Spain
View all 56 locations
View Trial Details
Completed

A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib

NCT01324596

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Kantonsspital Aarau Aarau, Switzerland
  • Kantonsspital Liestal Basel, Switzerland
  • Universitatsspital Basel Basel, Switzerland
  • Ospedale Regionale Bellinzona e Valli (IOSI) Bellinzona, Switzerland
View all 109 locations
View Trial Details
Completed

Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

NCT00765245

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States
  • Vanderbilt-Ingram Cancer Center - Cool Springs Nashville, Tennessee, United States
  • Vanderbilt-Ingram Cancer Center at Franklin Nashville, Tennessee, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
View Trial Details
Completed

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

NCT01410513

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +19 more
Locations
  • Investigational Site Number 840004 Aurora, Colorado, United States
  • Investigational Site Number 840006 Augusta, Georgia, United States
  • Investigational Site Number 840002 Charleston, South Carolina, United States
View Trial Details
Completed

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

NCT01433731

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Stanford University Stanford, California, United States
  • Northwestern University Dept of Dermatology Chicago, Illinois, United States
  • University Hospitals Case Medical Center Cleveland, Ohio, United States
  • Cleveland Clinic Cleveland, Ohio, United States
View Trial Details

Related conditions